Multiple Locations, Canada
NCT Number: NCT02536534
Electronic Activity Level Monitoring Pilot in Pulmonary Hypertension
Evaluate the correlation between activity level (monitored by Fitbit Flex remote activity tracker) and 6-minute walk distance (6MWD) (performed by investigator) in patients with Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) over 6 months in routine clinical practice settings.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
About this study
Remote patient monitoring can lead to improved patient outcomes, including improved quality of life, reduced readmissions, earlier treatment for symptoms detected prior to schedule in-office follow-up visits, improved communications with care providers, increased participation in self-management of disease, and an improved knowledge of their medical conditions . In patients with PAH, daily activity level, as measured using a physical activity monitor for seven consecutive days, correlated with 6-minute walk distance (6MWD). The monitor used in the aforementioned PAH study was positioned on the patients' right upper arm with an armband, as opposed to the more popular and more comfortable wristbands used today, such as the Fitbit Flex. Although the aforementioned PAH study did show a correlation between activity level monitoring and 6MWD, the patients were monitored for only seven days. It is still unknown whether this correlation would exist over a longer trial period and whether patients, their caregivers, and clinicians would find activity level monitoring useful in helping manage PH.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Male or female patients with a diagnosis of Pulmonary Arterial Hypertension (PAH); or inoperable, persistent or recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH),
- Age ≥ 18 years,
- Baseline 6 Minute Walk Distance (6MWD) a minimum of 250 meters or maximum 450 meters, (ensure significant Pulmonary Hypertension(PH) without limiting their participation in the trial)
- WHO Functional Class II or III,
- Clinically stable patient defined as within the last 12 months (minimum of 3 months) prior to enrollment, there was no:
- decline in World Health Organization (WHO) Function class or,
- decline in 6MWD by 15% or,
- change of oral PAH/CTEPH therapy (may have flexible diuretics/anticoagulation) or,
- Introduction of parenteral Prostacyclin Analog (PCA) treatment.
- Patients provide written informed consent, are able to understand and follow instructions.
Exclusion criteria
- Hypersensitivity to nickel (present in the clasp of the FitBit Flex's band),
- Medical disorder, condition, or history of such that would impair the patient's ability to participate or complete this study in the opinion of the investigator,
- Enrolled in pulmonary rehabilitation program within last 6 months,
- Participating in an interventional study.
Treatment and study plan
Correlation assessment
OtherPrimary outcomes
-
6-minute walk distance (6MWD)
Time frame: At baseline
(performed by investigator)
-
6-minute walk distance (6MWD)
Time frame: At 3 months
(performed by investigator)
-
6-minute walk distance (6MWD)
Time frame: At 6 months
(performed by investigator)
-
Number of steps per day
Time frame: At baseline
(monitored by Fitbit Flex)
-
Number of steps per day
Time frame: At 3 months
(monitored by Fitbit Flex)
-
Number of steps per day
Time frame: At 6 months
(monitored by Fitbit Flex)
Secondary outcomes
-
Change in quality of life recorded by patient questionnaire Living with Pulmonary hypertension Questionnaire (LPH)
Time frame: At baseline, 3 months and 6 months
-
Change in compliance with medication using the Moriky´s Questionnaire
Time frame: At baseline, 3 months and 6 months
-
Change in World Health Organization (WHO) functional Class recorded by investigator in conjunction with the 6MWD
Time frame: At baseline, 3 months and 6 months
-
Change in Borg Dyspnea value recorded by investigator in conjunction with the 6MWD
Time frame: At baseline, 3 months and 6 months
-
Healthcare provider Satisfaction and Usability questionnaire
Time frame: At 3 months and 6 months
-
Caregiver Satisfaction and Usability questionnaire
Time frame: At 3 months and 6 months
-
Patient Satisfaction and Usability questionnaire
Time frame: At 3 months and 6 months
Sponsors and collaborators
Lead sponsor
Bayer
Industry
Registry information
Official study title
(e-MOTION PH) Electronic - Activity Level Monitoring Pilot in Pulmonary Hypertension
Acronym: e-MOTION PH
Important dates
- Study start
- 2015
- Primary completion
- 2016
- Study completion
- 2016
- First posted
- Sep 1, 2015
- Registry last updated
- Dec 20, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
NCT03626688
Cardiovascular Diseases, Connective Tissue Diseases
Birmingham, Alabama, United States
View Trial DetailsA Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)
NCT04732221
Cardiovascular Diseases, Hypertension
La Jolla, California, United States
View Trial DetailsThis Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
NCT03754660
Cardiovascular Diseases, Hypertension
Graz, Austria
View Trial DetailsNon-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)
NCT02825160
Cardiovascular Diseases, Hypertension
Multiple Locations, Japan
View Trial Details